Quell Therapeutics Limited
- Address
- 3rd Floor, Translation And Innovation Hub, 84 Wood Lane
Sponsor Overview
Specializations
Transplant Immunology
Clinical research in liver transplantation with attention to graft rejection and immune tolerance in A2-mismatch transplant settings.
- Prevention of liver transplant rejection
- Allogeneic immune regulation
- Post-transplant immunological compatibility
The sponsor’s transplant-focused work centers on immune-mediated complications that affect organ acceptance and long-term transplant outcomes.
Systemic Sclerosis
Research activity includes diffuse cutaneous systemic sclerosis, with emphasis on the immune and fibrotic disease processes that drive skin and internal organ involvement.
- Diffuse cutaneous systemic sclerosis (dcSSc)
- Fibrosis-related immune disease
- Autoimmune connective tissue disorders
This area reflects a therapeutic interest in severe systemic autoimmune disease with progressive tissue remodeling.
Rheumatology
The sponsor is also active in rheumatoid arthritis, particularly difficult-to-manage disease forms associated with persistent inflammation and treatment resistance.
- Difficult to treat rheumatoid arthritis (D2TRA)
- Chronic inflammatory arthritis
- Autoimmune joint disease
Its rheumatology portfolio focuses on immune-driven joint disease where durable control of inflammation remains a key therapeutic need.
Cell-Based Immunotherapy
Across its clinical program, the company is developing cell therapy approaches aimed at modifying pathogenic immune responses in both autoimmune and transplant-related conditions.
- Engineered immune cell therapies
- Targeted immunomodulation
- Immune tolerance restoration
This therapeutic domain links the sponsor’s work in autoimmunity and transplant medicine through immune system reprogramming.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase I/II Evaluation of QEL-001, Autologous CAR T Regulatory Cells, for Safety in HLA-A2 Mismatch Liver Transplant Rejection Prevention |  Belgium Spain | Not Recruiting |
| Phase I/II Study of QEL-005 Autologous CD19-Targeting CAR T-Regulatory Cell Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis and Difficult-to-Treat Rheumatoid Arthritis |  Germany Spain | Not Yet Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 9 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune system processes1 trial65 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
Partnered Research Centres
9 centres- Address
- Hippokrateslaan 10, Batiment 54, 1200 Woluwe-Saint-Lambert
- Address
- Calle Villarroel 170, 08036 Barcelona
- Address
- Calle Del Doctor Esquerdo 46, 28007 Madrid
- Address
- Avenida De Los Reyes Catolicos 2, 28040 Madrid
- Address
- Mijlenmeersstraat 90, 1070 Anderlecht
- Address
- Herestraat 49, 3000 Leuven
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Quell Therapeutics Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.